Monte Rosa Therapeutics, Inc.
GLUE
$16.86
$1.459.41%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 117.54% | 118.53% | 104.55% | 46.29% | 10.15% |
| Total Depreciation and Amortization | 11.06% | 14.67% | 12.05% | 22.69% | 28.86% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 5.04% | -6.07% | -0.25% | 21.62% | 16.51% |
| Change in Net Operating Assets | 163.19% | -143.50% | -89.70% | 26.12% | 134.31% |
| Cash from Operations | 360.31% | 145.43% | 159.20% | 195.88% | 41.18% |
| Capital Expenditure | 25.08% | 42.79% | 62.73% | 79.06% | 77.69% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -100.00% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1,119.20% | -1,294.42% | -267.96% | -137.54% | -86.18% |
| Cash from Investing | -9,231.31% | -4,831.30% | -297.29% | -150.06% | -96.40% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -97.44% | -98.12% | 1,744.18% | 1,914.30% | 122.75% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -100.00% | -100.00% | 86.30% | 86.30% | 10,455.09% |
| Cash from Financing | -98.92% | -99.20% | 255.92% | 259.71% | 442.60% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 23.77% | -163.28% | -144.65% | 33.03% | 223.72% |